Effect of Elagolix Exposure on Clinical Efficacy End Points in Phase III Trials in Women With Endometriosis‐Associated Pain: An Application of Markov Model

Elagolix is an oral gonadotropin‐releasing hormone antagonist approved by the US Food and Drug Administration (FDA) for the management of moderate‐to‐severe pain associated with endometriosis and in combination with estradiol/norethindrone acetate approved for the management of heavy menstrual bleed...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:CPT Pharmacometrics Syst Pharmacol
Autori principali: Winzenborg, Insa, Polepally, Akshanth R., Nader, Ahmed, Mostafa, Nael M., Noertersheuser, Peter, Ng, Juki
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley and Sons Inc. 2020
Soggetti:
Research
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7438813/
https://ncbi.nlm.nih.gov/pubmed/32621325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/psp4.12545
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi